Singapore markets close in 2 hours 52 minutes
  • Straits Times Index

    3,164.40
    +10.81 (+0.34%)
     
  • Nikkei

    29,338.05
    +525.45 (+1.82%)
     
  • Hang Seng

    28,536.13
    +118.13 (+0.42%)
     
  • FTSE 100

    7,039.30
    +116.13 (+1.68%)
     
  • BTC-USD

    56,975.56
    +2,332.82 (+4.27%)
     
  • CMC Crypto 200

    1,459.55
    +54.24 (+3.86%)
     
  • S&P 500

    4,167.59
    +2.93 (+0.07%)
     
  • Dow

    34,230.34
    +97.34 (+0.29%)
     
  • Nasdaq

    13,582.42
    -51.08 (-0.37%)
     
  • Gold

    1,792.30
    +8.00 (+0.45%)
     
  • Crude Oil

    65.80
    +0.17 (+0.26%)
     
  • 10-Yr Bond

    1.5840
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,564.55
    -11.12 (-0.71%)
     
  • Jakarta Composite Index

    5,963.47
    -12.44 (-0.21%)
     
  • PSE Index

    6,282.78
    -16.91 (-0.27%)
     

Kaman Reports 2021 First Quarter Results

  • Oops!
    Something went wrong.
    Please try again later.
·30-min read
  • Oops!
    Something went wrong.
    Please try again later.

First Quarter Highlights:

  • Net sales from continuing operations of $171.6 million, down 17.2% over prior year period

  • Gross profit from continuing operations of $52.9 million; Gross margin of 30.8%

  • Earnings from continuing operations of $8.0 million, up $8.4 million over the prior year period

  • Diluted earnings per share from continuing operations of $0.29

  • Adjusted EBITDA from continuing operations* of $17.1 million decreased from the first quarter of 2020 but flat with the fourth quarter of 2020 on lower sales

  • Net cash used in operating activities of $2.4 million; Adjusted Free Cash Flow* of $18.0 million

Kaman Corp. (NYSE:KAMN) today reported financial results for the first fiscal quarter ended April 2, 2021.

Table 1. Summary of Financial Results (unaudited)

In thousands except per share amounts

For the Three Months Ended

April 2,
2021

April 3,
2020

Change

Net sales from continuing operations

$

171,616

$

207,322

$

(35,706

)

Operating income from continuing operations:

Operating income (loss) from continuing operations

$

5,613

$

(4,422

)

$

10,035

% of sales

3.3

%

(2.1

)%

5.4

%

Adjustments

$

2,291

$

21,117

$

(18,826

)

Adjusted operating income from continuing operations*

$

7,904

$

16,695

$

(8,791

)

% of sales

4.6

%

8.1

%

(3.5

)%

Adjusted EBITDA from continuing operations*:

Earnings (loss) from continuing operations

$

7,984

$

(407

)

$

8,391

Adjustments

9,129

26,611

(17,482

)

Adjusted EBITDA from continuing operations*

$

17,113

$

26,204

$

(9,091

)

% of sales

10.0

%

12.6

%

(2.6

)%

Earnings per share from continuing operations:

Diluted earnings per share from continuing operations

$

0.29

$

(0.01

)

$

0.30

Adjustments

0.49

(0.49

)

Adjusted diluted earnings per share from continuing operations*

$

0.29

$

0.48

$

(0.19

)

Ian K. Walsh, Chairman, President and Chief Executive Officer, commented, "We begin the year with a solid quarter and confidence in our end-market recovery seeing significant sequential improvements in our Medical and Industrial end markets with strong order rates for these products. Sales for our Defense and Commercial, Business and General Aviation products declined both year-over-year and sequentially due to lower JPF volume and the impact of COVID-19, respectively. Looking to the remainder of the year, our JPF program remains on track and we anticipate a significant ramp up in sales for our Commercial, Business and General Aviation products in the second half of the year and are encouraged by increased air traffic and vaccination rates in the United States."

"Our cost control efforts carried forward into the first quarter where we achieved Adjusted EBITDA* margin of 10.0%. This result demonstrates our ability to maintain profitability despite the year-over-year and sequential sales declines we experienced. We remain focused on implementing our operational excellence model that is designed to improve EBITDA Margin, Free Cash Flow, and Return on Invested Capital and we are starting to see positive results."

"New product development remains an important part of our future growth and we have made significant progress on a number of these initiatives, including the opening of our first production cell for highly engineered products utilizing our proprietary Titanium Diffusion Hardening process and the successful test flight for our new unmanned K-MAX TITAN TM system. This test flight is a significant milestone in enabling us to meet the future unmanned logistics requirements of our commercial and defense customers. As we look to the remainder of the year, we anticipate sequential organic growth and continued progress on our new product development efforts and our strategic acquisitions priorities."

Management's Commentary on First Quarter Results:

Net sales for the quarter decreased 17.2% when compared to the first quarter of 2020 and 7.4% sequentially. Organic sales*, which excludes sales from our former U.K. composite operations, decreased 14.5% from the first quarter of 2020 and decreased 5.6% from the fourth quarter of 2020. Sales declines were due to lower sales volume of our Defense products and our Commercial, Business and General Aviation products, partially offset by increased sales for our Medical and Industrial products.

Sales for our Defense products decreased 20.2% when compared to the first quarter of 2020 and 10.7% when compared to the fourth quarter of 2020. The sequential decrease was due in large part to lower volume for our Joint Programmable Fuze program offset by a modest increase in our other defense offerings. During the quarter we delivered 8,090 fuzes and we continue to expect to deliver 30,000 to 35,000 Joint Programmable Fuzes in the year.

Sales for our Commercial, Business and General Aviation products decreased 24.2% from the first quarter of 2020 and 14.8% from the fourth quarter of 2020. This sequential decrease was due to a 19.9% decrease in sales for our commercial aviation products and a 12.7% decrease in general and business aviation products. As we look to the remainder of the year we expect sales for these products to improve with a more significant increase in sales in the second half of the year.

Sales for our Medical products were relatively flat with the first quarter of 2020 and increased 22.8% when compared to the fourth quarter of 2020. This is our third straight quarter with improved sales for these product offerings and we saw very strong order intake in the first quarter for our medical miniature bearings, seals, springs, and contacts. Finally, our Industrial products also saw strong order activity in the quarter and delivered a 9.5% increase in sales over the first quarter of 2020 and 5.8% increase in sales over the fourth quarter of last year.

Commenting on the quarter, Chief Financial Officer, Robert D. Starr, stated, "First quarter diluted earnings per share was $0.29 on a GAAP and adjusted* basis. This result was led by solid gross margin in excess of 30% and, despite a sequential sales decline, selling, general, and administration expense as a percentage of sales remained flat with the fourth quarter of 2020 as we continued to focus on our cost control efforts. During the quarter, Net cash used in operating activities from continuing operations was $2.4 million and included a $25.1 million payment for the acquired retention plans at Bal Seal. Adjusted Free Cash Flow* for the period was $18.0 million and benefited from improved collections in the quarter. We are maintaining our previous full year outlook as we continue to anticipate a strong recovery in our Commercial Business and General Aviation products in the second half of the year."

2021 Outlook

(in millions)

2020

2021 Outlook

Actual

Low End

High End

Sales

Sales from continuing operations

$

784.5

$

725.0

$

745.0

Sales of Disposed Business(1)

21.5

Organic Sales

$

763.0

$

725.0

$

745.0

Adjusted EBITDA*

Earnings from continuing operations

$

(70.4

)

$

43.5

$

52.5

Adjustments

173.3

41.5

44.0

Adjusted EBITDA* from continuing operations

$

102.9

$

85.0

$

96.5

Adjusted EBITDA margin* from continuing operations

13.1

%

11.7

%

13.0

%

Adjusted Diluted Earnings Per Share*

Diluted Earnings Per Share

$

(2.54

)

$

1.55

$

1.87

Adjustments

4.65

Adjusted Diluted Earnings Per Share

$

2.11

$

1.55

$

1.87

Cash Flow

Operating cash flow from continuing operations

$

16.5

$

25.0

$

35.0

Bal Seal Acquisition Retention Payment

25.1

25.1

Cash used for the purchase of property, plant and equipment

(17.8

)

(20.0

)

(20.0

)

Adjusted Free Cash Flow*

$

(1.3

)

$

30.1

$

40.1

Discretionary Pension Contribution

$

10.0

$

10.0

$

10.0

(1) In the first quarter of 2021 the Company sold its U.K Composites Business which did not qualify for reporting as a discontinued operation under GAAP. In 2021 we will record sales of $1.7 million for this business which was not contemplated as part of our outlook for the year.

(2) Operating cash flow from continuing operations include the $25.1 million payment to Bal Seal employees which represents purchase price paid to the former Bal Seal owners that was accounted for as compensation expense under ASC 805 in 2020.

Please see the MD&A section of the Company's Form 10-Q filed with the Securities and Exchange Commission concurrently with the issuance of this release for greater detail on our results and various company programs.

A conference call has been scheduled for tomorrow, May 5, 2021, at 8:30 AM ET. The call will be accessible by telephone within the U.S. at (844) 473-0975 and from outside the U.S. at (562) 350-0826 (using the Conference I.D.: 7396055) or via the Internet at www.kaman.com. Please go to the website at least fifteen minutes prior to the start of the call to register, download and install any necessary audio software. A replay will also be available two hours after the call and can be accessed at (855) 859-2056 or (404) 537-3406 using the Conference I.D.: 7396055.

About Kaman Corporation

Kaman Corporation, founded in 1945 by aviation pioneer Charles H. Kaman, and headquartered in Bloomfield, Connecticut, conducts business in the Aerospace, Defense, Industrial and Medical markets. Kaman produces and markets proprietary aircraft bearings and components; super precision, miniature ball bearings; proprietary spring energized seals, springs and contacts; complex metallic and composite aerostructures for commercial, military and general aviation fixed and rotary wing aircraft; safe and arming solutions for missile and bomb systems for the U.S. and allied militaries; subcontract helicopter work; restoration, modification and support of our SH-2G Super Seasprite maritime helicopters; manufacture and support of our K-MAX® manned and unmanned medium-to-heavy lift helicopters.

More information is available at www.kaman.com.

Non-GAAP Measures Disclosure

Management believes that the Non-GAAP financial measures (i.e. financial measures that are not computed in accordance with Generally Accepted Accounting Principles) identified by an asterisk (*) used in this release or in other disclosures provide important perspectives into the Company's ongoing business performance. The Company does not intend for the information to be considered in isolation or as a substitute for the related GAAP measures. Other companies may define the measures differently. We define the Non-GAAP measures used in this release and other disclosures as follows:

Organic Sales - Organic Sales is defined as "Net Sales" less sales derived from acquisitions completed or businesses disposed of that did not qualify for accounting as a discontinued operation during the preceding twelve months. We believe that this measure provides management and investors with a more complete understanding of underlying operating results and trends of established, ongoing operations by excluding the effect of acquisitions, which can obscure underlying trends. We also believe that presenting Organic Sales enables a more direct comparison to other businesses and companies in similar industries. Management recognizes that the term "Organic Sales" may be interpreted differently by other companies and under different circumstances. No other adjustments were made during the three-month fiscal periods ended April 2, 2021 and April 3, 2020, respectively. The following table illustrates the calculation of Organic Sales using the GAAP measure, "Net Sales".

Table 2. Organic Sales from continuing operations (in thousands) (unaudited)

For the Three Months Ended

April 2,
2021

April 3,
2020

Net sales

$

171,616

$

207,322

Acquisition Sales

Sales of Disposed Business

1,704

8,486

Organic Sales

$

169,912

$

198,836

$ Change

(28,924

)

% Change

(14.5

)%

Adjusted Net Sales from continuing operations and Adjusted Operating Income from continuing operations - Adjusted Net Sales from continuing operations is defined as net sales from continuing operations, less items not indicative of normal sales, such as revenue recorded related to the settlement of claims. Adjusted Operating Income from continuing operations is defined as operating income from continuing operations, less items that are not indicative of the operating performance of the Company for the period presented. These items are included in the reconciliation below. Management uses Adjusted Net Sales from continuing operations and Adjusted Operating Income from continuing operations to evaluate performance period over period, to analyze underlying trends and to assess our performance relative to our competitors. We believe that this information is useful for investors and financial institutions seeking to analyze and compare companies on the basis of operating performance. The following table illustrates the calculation of Adjusted Operating Income from continuing operations to the Consolidated Financial Statements included in the Company's Form 10-Q filed with the Securities and Exchange Commission on May 4, 2021.

Table 3. Adjusted Net Sales and Adjusted Operating Income from Continuing Operations

(In thousands) (unaudited)

For the Three Months Ended

April 2,
2021

April 3,
2020

CONSOLIDATED OPERATING INCOME:

Net Sales from continuing operations

$

171,616

$

207,322

GAAP - Operating income (loss) from continuing operations

$

5,613

$

(4,422

)

% of GAAP net sales

3.3

%

(2.1

)%

Adjustments

Restructuring and severance costs

1,352

1,795

Costs associated with corporate development activities

1,787

Bal Seal acquisition costs

8,483

Cost of acquired Bal Seal retention plans

5,703

Inventory step-up associated with Bal Seal acquisition

1,177

Costs from transition services agreement

705

4,140

Reversal of employee tax-related matters in foreign operations

(1,211

)

Reversal of environmental accrual at GRW

(264

)

Loss (gain) on sale business

234

(493

)

Total adjustments

$

2,291

$

21,117

Adjusted Operating Income

$

7,904

$

16,695

% of GAAP net sales

4.6

%

8.1

%

Adjusted EBITDA from continuing operations - Adjusted EBITDA from continuing operations is defined as earnings from continuing operations before interest, taxes, other expense (income), net, depreciation and amortization and certain items that are not indicative of the operating performance of the Company for the periods presented. Adjusted EBITDA from continuing operations differs from earnings from continuing operations, as calculated in accordance with GAAP, in that it excludes interest expense, net, income tax expense, depreciation and amortization, other expense (income), net, non-service pension and post retirement benefit expense (income), and certain items that are not indicative of the operating performance of the Company for the periods presented. We have made numerous investments in our business, such as acquisitions and capital expenditures, including facility improvements, new machinery and equipment, improvements to our information technology infrastructure and ERP systems, which we have adjusted for in Adjusted EBITDA from continuing operations. Adjusted EBITDA from continuing operations also does not give effect to cash used for debt service requirements and thus does not reflect funds available for distributions, reinvestments or other discretionary uses. Management believes Adjusted EBITDA from continuing operations provides an additional perspective on the operating results of the organization and its earnings capacity and helps improve the comparability of our results between periods because it provides a view of our operations that excludes items that management believes are not reflective of operating performance, such as items traditionally removed from net earnings in the calculation of EBITDA as well as Other expense (income), net and certain items that are not indicative of the operating performance of the Company for the period presented. Adjusted EBITDA from continuing operations is not presented as an alternative measure of operating performance, as determined in accordance with GAAP. No other adjustments were made during the three-month fiscal periods ended April 2, 2021 and April 3, 2020. The following table illustrates the calculation of Adjusted EBITDA from continuing operations using GAAP measures:

Table 4. Adjusted EBITDA from continuing operations (in thousands) (unaudited)

For the Three Months Ended

April 2,
2021

April 3,
2020

Adjusted EBITDA from continuing operations

Consolidated Results

Sales from continuing operations

$

171,616

$

207,322

Earnings (loss) from continuing operations, net of tax

7,984

(407

)

Interest expense, net

4,251

3,247

Income tax expense (benefit)

207

(443

)

Non-service pension and post retirement benefit income

(6,643

)

(4,063

)

Other expense, net

289

218

Depreciation and amortization

9,209

9,509

Other Adjustments:

Restructuring and severance costs

1,352

1,795

Cost associated with corporate development activities

1,787

Bal Seal acquisition costs

8,483

Cost of acquired Bal Seal retention plans

5,703

Inventory step-up associated with Bal Seal acquisition

1,177

Costs from transition services agreement

705

4,140

Income from transition services agreement

(475

)

(2,974

)

Reversal of employee tax-related matters in foreign operations

(1,211

)

Reversal of environmental accrual at GRW

(264

)

Loss (gain) on sale of business

234

(493

)

Adjustments

$

9,129

$

26,611

Adjusted EBITDA from continuing operations

$

17,113

$

26,204

Adjusted EBITDA margin

10.0

%

12.6

%

Adjusted Earnings from Continuing Operations and Adjusted Diluted Earnings Per Share from Continuing Operations - Adjusted Earnings from Continuing Operations and Adjusted Diluted Earnings per Share from Continuing Operations are defined as GAAP "Earnings from Continuing Operations" and "Diluted earnings per share from continuing operations", less items that are not indicative of the operating performance of the business for the periods presented. These items are included in the reconciliation below. Management uses Adjusted Earnings from Continuing Operations and Adjusted Diluted Earnings per Share from Continuing Operations to evaluate performance period over period, to analyze the underlying trends in our business and to assess its performance relative to its competitors. We believe that this information is useful for investors and financial institutions seeking to analyze and compare companies on the basis of operating performance.

The following table illustrates the calculation of Adjusted Earnings from Continuing Operations and Adjusted Diluted Earnings per Share from Continuing Operations using "Earnings from Continuing Operations" and "Diluted earnings per share from continuing operations" from the "Consolidated Statements of Operations" included in the Company's Form 10-Q filed with the Securities and Exchange Commission on May 4, 2021.

Table 5. Adjusted Earnings from continuing operations and Adjusted Diluted Earnings per Share from continuing operations

(In thousands except per share amounts) (unaudited)

For the Three Months Ended

April 2,
2021

April 3,
2020

Adjustments to Earnings from Continuing Operations

Restructuring and severance costs

$

1,352

$

1,795

Costs associated with corporate development activities

1,787

Bal Seal acquisition costs

8,483

Cost of acquired Bal Seal retention plans

5,703

Inventory step-up associated with Bal Seal acquisition

1,177

Costs from transition services agreement

705

4,140

Income from transition services agreement

(475

)

(2,974

)

Reversal of employee tax-related matters in foreign operations

(1,211

)

Reversal of environmental accrual at GRW

(264

)

Tax benefit on sale of UK operations

(1,512

)

Loss (gain) on sale of business

234

(493

)

Adjustments, pre tax

$

304

$

18,143

Tax Effect of Adjustments to Earnings from Continuing Operations

Restructuring and severance costs

$

273

$

434

Costs associated with corporate development activities

432

Bal Seal acquisition costs

2,050

Cost of acquired Bal Seal retention plans

1,378

Inventory step-up associated with Bal Seal acquisition

284

Costs from transition services agreement

142

1,001

Income from transition services agreement

(96

)

(719

)

Employee tax-related matters in foreign operations

(293

)

Reversal of environmental accrual at GRW

(64

)

Tax benefit on sale of UK operations

Loss (gain) on sale of business

(119

)

Tax effect of Adjustments

$

319

$

4,384

Adjustments to Earnings from Continuing Operations, net of tax

GAAP Earnings (loss) from continuing operations, as reported

$

7,984

$

(407

)

Restructuring and severance costs

1,079

1,361

Costs associated with corporate development activities

1,355

Bal Seal acquisition costs

6,433

Cost of acquired Bal Seal retention plans

4,325

Inventory step-up associated with Bal Seal acquisition

893

Costs from transition services agreement

563

3,139

Income from transition services agreement

(379

)

(2,255

)

Employee tax-related matters in foreign operations

(918

)

Reversal of environmental accrual at GRW

(200

)

Tax benefit on sale of U.K. Operations

(1,512

)

Loss (gain) on sale of business

234

(374

)

Adjusted Earnings from continuing operations

$

7,969

$

13,352

Calculation of Adjusted Diluted Earnings per Share from Continuing Operations

GAAP diluted earnings (loss) per share from continuing operations

$

0.29

$

(0.01

)

Restructuring and severance costs

0.03

0.05

Costs associated with corporate development activities

0.05

Bal Seal acquisition costs

0.23

Cost of accrued Bal Seal retention plans

0.15

Inventory step-up associated with Bal Seal acquisition

0.03

Costs from transition services agreement

0.02

0.11

Income from transition services agreement

(0.01

)

(0.08

)

Employee tax-related matters in foreign operations

(0.03

)

Reversal of environmental accrual at GRW

(0.01

)

Tax benefit on sale of UK operations

(0.05

)

Loss (gain) on sale of business

0.01

(0.01

)

Adjustments to diluted earnings per share from continuing operations

$

$

0.49

Adjusted Diluted Earnings per Share from continuing operations

$

0.29

$

0.48

Diluted weighted average shares outstanding

27,867

27,891

Adjusted Free Cash Flow from continuing operations - Adjusted Free Cash Flow from continuing operations is defined as GAAP "Net cash provided by (used in) operating activities from continuing operations" in a period less "Expenditures for property, plant & equipment" in the same period and any adjustments that are representative of the Company's cash generation or usage in the period. For 2021 we will adjust free cash flow to remove the cash payment made to Bal Seal employees under the retention plan established by the former owners of Bal Seal. Management believes Free Cash Flow from continuing operations and Adjusted Free Cash Flow provides an important perspective on our ability to generate cash from our business operations and, as such, that it is an important financial measure for use in evaluating the Company's financial performance. Free Cash Flow from continuing operations and Adjusted Free Cash Flow should not be viewed as representing the residual cash flow available for discretionary expenditures such as dividends to shareholders or acquisitions, as it may exclude certain mandatory expenditures such as repayment of maturing debt and other contractual obligations. Management uses Free Cash Flow from continuing operations and Adjusted Free Cash Flow internally to assess overall liquidity. The following table illustrates the calculation of Adjusted Free Cash Flow from continuing operations using "Net cash provided by (used in) operating activities from continuing operations", "Expenditures for property, plant & equipment" and "Cash paid for acquired retention plans", GAAP measures from the Condensed Consolidated Statements of Cash Flows included in this release.

Table 6. Adjusted Free Cash Flow from continuing operations (in thousands) (unaudited)

For the Three Months Ended

April 2, 2021

Net cash used in operating activities from continuing operations

$

(2,415

)

Expenditures for property, plant & equipment

(4,678

)

Cash paid for acquired retention plans (1)

25,108

Adjusted Free Cash Flow from continuing operations

$

18,015

(1) Operating cash flow from continuing operations will include the $25.1 million payment to Bal Seal employees which represents purchase price paid to the former Bal Seal owners accounted for as compensation under ASC 805

Debt to Capitalization Ratio - Debt to Capitalization Ratio is calculated by dividing debt by capitalization. Debt is defined as GAAP "Current portion of long-term debt" plus "Long-term debt, excluding current portion". Capitalization is defined as Debt plus GAAP "Total shareholders' equity". Management believes that Debt to Capitalization Ratio is a measurement of financial leverage and provides an insight into the financial structure of the Company and its financial strength. The following table illustrates the calculation of Debt to Capitalization Ratio using GAAP measures from the Condensed Consolidated Balance Sheets included in this release.

Table 7. Debt to Capitalization Ratio (in thousands) (unaudited)

April 2, 2021

December 31, 2020

Long-term debt, excluding current portion

$

186,378

$

185,401

Debt

186,378

185,401

Total shareholders' equity

767,219

746,438

Capitalization

$

953,597

$

931,839

Debt to Capitalization Ratio

19.5

%

19.9

%

FORWARD-LOOKING STATEMENTS

This release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management's current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "would," "could," "will" and other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance.

Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company's actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others: (i) risks related to Kaman's performance of its obligations under the transition services agreement entered into in connection with the sale of our former Distribution business and UK Composites business and disruption of management time from ongoing business operations relating thereto; (ii) changes in domestic and foreign economic and competitive conditions in markets served by the Company, particularly the defense, commercial aviation and industrial production markets; (iii) changes in government and customer priorities and requirements (including cost-cutting initiatives, government and customer shut-downs, the potential deferral of awards, terminations or reductions of expenditures to respond to the priorities of Congress and the Administration, or budgetary cuts resulting from Congressional actions, including the elimination of Overseas Contingency Operations funding, or automatic sequestration); (iv) the global economic impact of the COVID-19 pandemic; (v) changes in geopolitical conditions in countries where the Company does or intends to do business; (vi) the successful conclusion of competitions for government programs (including new, follow-on and successor programs) and thereafter successful contract negotiations with government authorities (both foreign and domestic) for the terms and conditions of the programs; (vii) the timely receipt of any necessary export approvals and/or other licenses or authorizations from the USG; (viii) timely satisfaction or fulfillment of material contractual conditions precedents in customer purchase orders, contracts, or similar arrangements; (ix) the existence of standard government contract provisions permitting renegotiation of terms and termination for the convenience of the government; (x) the successful resolution of government inquiries or investigations relating to our businesses and programs; (xi) risks and uncertainties associated with the successful implementation and ramp up of significant new programs, including the ability to manufacture the products to the detailed specifications required and recover start-up costs and other investments in the programs; (xii) potential difficulties associated with variable acceptance test results, given sensitive production materials and extreme test parameters; (xiii) the receipt and successful execution of production orders under the Company's existing USG JPF contract, including the exercise of all contract options and receipt of orders from allied militaries, but excluding any next generation programmable fuze programs, as all have been assumed in connection with goodwill impairment evaluations; (xiv) the continued support of the existing K-MAX® helicopter fleet, including sale of existing K-MAX® spare parts inventory and the receipt of orders for new aircraft sufficient to recover our investments in the K-MAX® production line; (xv) the accuracy of current cost estimates associated with environmental remediation activities; (xvi) the profitable integration of acquired businesses into the Company's operations; (xvii) the ability to recover from cyber-based or other security attacks, information technology failures or other disruptions, including the December 2020 Bal Seal incident; (xviii) changes in supplier sales or vendor incentive policies; (xix) the ability of our suppliers to satisfy their performance obligations; (xx) the effects of price increases or decreases; (xxi) the effects of pension regulations, pension plan assumptions, pension plan asset performance, future contributions and the pension freeze, including the ultimate determination of the USG's share of any pension curtailment adjustment calculated in accordance with CAS 413; (xxii) future levels of indebtedness and capital expenditures; (xxiii) the continued availability of raw materials and other commodities in adequate supplies and the effect of increased costs for such items; (xxiv) the effects of currency exchange rates and foreign competition on future operations; (xxv) changes in laws and regulations, taxes, interest rates, inflation rates and general business conditions; (xxvi) future repurchases and/or issuances of common stock; (xxvii) the occurrence of unanticipated restructuring costs or the failure to realize anticipated savings or benefits from past or future expense reduction actions; (xxviii) the ability to recruit and retain skilled employees; and (xxix) other risks and uncertainties set forth herein and in our 2020 Form 10-K and our First Quarter Form 10-Q filed May 4, 2021.

Any forward-looking information provided in this release should be considered with these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.

KAMAN CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts) (unaudited)

For the Three Months Ended

April 2,
2021

April 3,
2020

Net sales

$

171,616

$

207,322

Cost of sales

118,711

139,620

Gross profit

52,905

67,702

Selling, general and administrative expenses

44,991

60,989

Costs from transition services agreement

705

4,140

Cost of acquired retention plans

5,703

Restructuring and severance costs

1,352

1,795

Loss (gain) on sale of business

234

(493

)

Net loss (gain) on sale of assets

10

(10

)

Operating income (loss)

5,613

(4,422

)

Interest expense, net

4,251

3,247

Non-service pension and post retirement benefit income

(6,643

)

(4,063

)

Income from transition services agreement

(475

)

(2,974

)

Other expense, net

289

218

Earnings (loss) from continuing operations before income taxes

8,191

(850

)

Income tax expense (benefit)

207

(443

)

Earnings (loss) from continuing operations

7,984

(407

)

Earnings from discontinued operations before gain on disposal, net of tax

Gain on disposal of discontinued operations, net of tax

692

Total earnings from discontinued operations

692

Net earnings

$

7,984

$

285

Earnings per share:

Basic earnings (loss) per share from continuing operations

$

0.29

$

(0.01

)

Basic earnings per share from discontinued operations

0.02

Basic earnings per share

$

0.29

$

0.01

Diluted earnings (loss) per share from continuing operations

$

0.29

$

(0.01

)

Diluted earnings per share from discontinued operations

0.02

Diluted earnings per share

$

0.29

$

0.01

Average shares outstanding:

Basic

27,815

27,809

Diluted

27,867

27,891

KAMAN CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts) (unaudited)

April 2, 2021

December 31, 2020

Assets

Current assets:

Cash and cash equivalents

$

120,724

$

104,377

Restricted cash

25,121

Accounts receivable, net

102,328

153,806

Contract assets

114,601

108,645

Contract costs, current portion

5,050

3,511

Inventories

197,303

185,072

Income tax refunds receivable

4,851

5,269

Other current assets

12,628

12,173

Total current assets

557,485

597,974

Property, plant and equipment, net of accumulated depreciation of $233,534 and $228,984, respectively

207,145

210,852

Operating right-of-use assets, net

12,048

12,880

Goodwill

243,688

247,244

Other intangible assets, net

146,626

150,198

Deferred income taxes

37,540

39,809

Contract costs, noncurrent portion

7,205

8,311

Other assets

39,000

39,125

Total assets

$

1,250,737

$

1,306,393

Liabilities and Shareholders’ Equity

Current liabilities:

Accounts payable – trade

$

45,887

$

60,200

Accrued salaries and wages

40,306

70,552

Contract liabilities, current portion

32,622

39,073

Operating lease liabilities, current portion

4,057

4,305

Income taxes payable

1,203

19

Liabilities held for sale, current portion

18,086

Other current liabilities

35,722

36,177

Total current liabilities

159,797

228,412

Long-term debt, excluding current portion, net of debt issuance costs

186,378

185,401

Deferred income taxes

7,205

7,381

Underfunded pension

63,185

69,610

Contract liabilities, noncurrent portion

12,120

11,019

Operating lease liabilities, noncurrent portion

8,632

9,325

Liabilities held for sale, noncurrent portion

1,171

Other long-term liabilities

46,201

47,636

Commitments and contingencies

Shareholders' equity:

Preferred stock, $1 par value, 200,000 shares authorized; none outstanding

Common stock, $1 par value, 50,000,000 shares authorized; voting; 30,370,157 and 30,278,668 shares issued, respectively

30,370

30,279

Additional paid-in capital

241,444

238,829

Retained earnings

730,913

728,764

Accumulated other comprehensive income (loss)

(114,466

)

(130,821

)

Less 2,564,358 and 2,555,785 shares of common stock, respectively, held in treasury, at cost

(121,042

)

(120,613

)

Total shareholders’ equity

767,219

746,438

Total liabilities and shareholders’ equity

$

1,250,737

$

1,306,393

KAMAN CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(In thousands) (unaudited)

For the Three Months Ended

April 2,
2021

April 3,
2020

Cash flows from operating activities:

Net earnings

$

7,984

$

285

Less: Total earnings from discontinued operations

692

Earnings (loss) from continuing operations

$

7,984

$

(407

)

Adjustments to reconcile net earnings from continuing operations to net cash (used in) provided by operating activities of continuing operations:

Depreciation and amortization

9,209

9,509

Amortization of debt issuance costs

424

492

Accretion of convertible notes discount

738

702

Provision for doubtful accounts

173

179

Loss (gain) on sale of business

234

(493

)

Net loss (gain) on sale of assets

10

(10

)

Net loss on derivative instruments

590

983

Stock compensation expense

1,743

1,633

Deferred income taxes

1,793

3,493

Changes in assets and liabilities, excluding effects of acquisitions/divestitures:

Accounts receivable

50,254

(6,531

)

Contract assets

(5,704

)

(11,665

)

Contract costs

(432

)

(709

)

Inventories

(13,655

)

(25,206

)

Income tax refunds receivable

418

(2,078

)

Operating right of use assets

799

1,223

Other assets

1,042

(917

)

Accounts payable - trade

(14,707

)

(6,405

)

Contract liabilities

(5,439

)

1,743

Operating lease liabilities

(908

)

(1,183

)

Acquired retention plan payments

(25,108

)

Other current liabilities

(6,796

)

(8,079

)

Income taxes payable

1,173

(1,038

)

Pension liabilities

(5,452

)

(12,887

)

Other long-term liabilities

(798

)

2,209

Net cash used in operating activities of continuing operations

(2,415

)

(55,442

)

Net cash used in operating activities of discontinued operations

Net cash used in operating activities

(2,415

)

(55,442

)

Cash flows from investing activities:

Proceeds from sale of assets

54

11

Proceeds from sale of discontinued operations

5,223

Proceeds from sale of business, net of cash on hand

(3,428

)

493

Expenditures for property, plant & equipment

(4,678

)

(5,559

)

Acquisition of businesses, net of cash acquired

(304,342

)

Other, net

(48

)

394

Net cash used in investing activities of continuing operations

(8,100

)

(303,780

)

Net cash used in investing activities of discontinued operations

Net cash used in investing activities

(8,100

)

(303,780

)

Cash flows from financing activities:

Net borrowings under revolving credit agreements

201,100

Net change in bank overdraft

797

371

Proceeds from exercise of employee stock awards

880

1,455

Purchase of treasury shares

(344

)

(14,072

)

Dividends paid

(5,545

)

(5,595

)

Other, net

(472

)

(381

)

Net cash (used in) provided by financing activities of continuing operations

(4,684

)

182,878

Net cash provided by financing activities of discontinued operations

Net cash (used in) provided by financing activities

(4,684

)

182,878

Net decrease in cash and cash equivalents

(15,199

)

(176,344

)

Effect of exchange rate changes on cash and cash equivalents

(166

)

262

Cash and cash equivalents and restricted cash at beginning of period

136,089

471,540

Cash and cash equivalents and restricted cash at end of period

$

120,724

$

295,458

View source version on businesswire.com: https://www.businesswire.com/news/home/20210504006265/en/

Contacts

James Coogan
V.P., Investor Relations and Corporate Development
(860) 243-6342
James.Coogan@kaman.com